Vaxxas Pty. Ltd. and the Coalition for Epidemic Preparedness Innovations are progressing heat-stable, dried-formulation mRNA vaccines using Vaxxas’ needle-free high-density microarray patch.
The Chinese government blacklisted several American companies, including gene sequencing-focused biotechnology firm Illumina Inc. and fashion brand PVH Corp., citing threats to China’s “national sovereignty, security and development interests.”
U.S. federal law is still lacking where AI is concerned, but California’s attorney general issued a bulletin that elevates the legal hazards of AI in medical use. The bulletin says that AI tools may not supplant a physician’s decision-making, a provision that would seem to render some FDA-cleared products illegal there.
C the Signs Ltd. recently received a capital injection of $8 million from Khosla Ventures to expand its AI-powered cancer prediction platform to the U.S. market.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aclarion, Akura Medical, Ambry Genetics, Avantik, Cardio Diagnostics , Catheter Precision, Movano, Pathmaker Neurosystems, Neuroone, Swing Therapeutics, Tempus AI, Theranica.
New hires and promotions in the med-tech industry, including: Airs Medical, Artedrone, Bio-Techne, Cytovale, FDA, Get Well, Iantrek, Medrhythms, Pulse Biosciences, Trisalus Life Sciences.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Femasys, Gyder, Rapidai.
Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that confirms their pregnancy – and a one in seven chance of developing the condition which can have long-term implications for both mother and child. Research out of the University of Virginia and Weill Cornell Medicine could soon change that by identifying biomarkers in the third trimester of pregnancy that indicate which women have the greatest risk of developing PPD.
RSS
